H

ello, everyone, and how are you are doing? STAT reporter Rebecca Robbins here, and I’m doing fine this morning, thanks to a steaming cup of stimulation. (No special flavor, though, I’m sorry to report.) Let’s get started on what you came here for: headlines from the world of pharma. And do send us a note if you spot anything interesting …

Novo Nordisk (NVO) scored a victory with its type 2 diabetes drug semaglutide in a late-stage trial, Reuters informs us. The drug combined with metformin successfully reduced glucose levels when tested head-to-head against a competitor from Eli Lilly (LLY).

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy